News 14.10.2026 Securecell and Beckman Coulter Life Sciences are collaborating on the integration of the Vi-CELL BLU Cell Viability Analyzer with Securecell's Numera® 3 automated sampling platform, creating a more automated workflow for cell culture monitoring. The new integration will combine automated liquid sample transfer with digital connectivity to enable a more seamless...
News 13.10.2026 The Schlieren-based company, led by CEO and co-founder Estelle Clerc, won the Environmental Award at the 2026 Swiss Future Awards. B Lab Switzerland and the PETRAM Foundation present this award to recognize sustainable solutions that are revolutionizing their industries and markets. Cellx BioSolutions received the award for its bacterial separation technology,...
News 12.10.2026 Gene therapies are used to treat many different blood disorders. However, blood stem cells often fail to achieve their full potential after transplantation. UZH researchers have now explored an alternative signaling pathway that could provide a remedy. Blood stem cells are rare cells in the bone marrow that produce the blood...
News 23.09.2026 Schlieren/Tokyo - Swiss Bioscience, based in Schlieren in the canton of Zurich, and the biotech company OrganTech from Tokyo are exploring a strategic collaboration. This will involve the regulatory development, manufacturing and commercialization of OrganTech’s hair regeneration technologies by Swiss Bioscience. (CONNECT) OrganTech has selected Swiss Bioscienceas its preferred strategic partner...
News 10.09.2026 ZURICH, Switzerland--(BUSINESS WIRE)--CDR-Life, Inc., a clinical-stage biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases, today announced its newest development candidate, CDR209, a novel T cell engager for the treatment of axial spondyloarthritis (axSpA) and potentially other HLA-B27 associated autoimmune diseases. "CDR209 represents an important...